The preoperative management of locally advanced rectal cancer has evolved over the years to establish fluoropyrimidine-based chemoradiation as the usual standard of care. With the advent of newer agents -chemotherapeutic and biologic -for treatment of colorectal cancer, their role in this setting is being evaluated as well. This review is focusing on up-to-date data and studies regarding preoperative treatment of locally advanced rectal cancer.
It is an adenocarcinoma, and surgical resection remains the only therapeutic modality offering a chance of cure. However, compared to cancers of the colon, rectal malignancies are more difficult to resect. The lack of a robust mesentery, coupled with the rectum's proximity to other genitourinary organs and the pelvic wall make complete surgical resection for T3-T4 and/or N1-N2 tumours difficult. For most stage I |(T1-T2, N0) disease (AJCC 7th Edition), complete surgical resection with clear margins usually suffices. 2, 3 However, for locally advanced rectal cancer [hereby defined as some T2 tumours (low and/or anterior rectum) and most T3, T4 or N1-N2 disease], surgical resection alone is not sufficient. 2, 3 Therefore, radiation and chemotherapy have evolved as important adjuncts in rectal cancer treatment, to allow better local outcomes. Over the years, the role of these adjunctive therapies has grown and various studies are available to guide therapy decisions.
Preoperative Radiation in Rectal Cancer
The first major randomised trial to evaluate adjunctive therapy for rectal cancer was the Swedish study -it compared preoperative radiation and surgery to surgery alone, and demonstrated improved local recurrence and overall survival with the addition of 25 Gy radiation preoperatively. 4, 5 This was followed by the Dutch study, which also used 25 Gy radiation prior to total mesorectal excision (TME). Again, improved local recurrence rates were seen; early overall survival, however, was not affected. 6 These results, combined with the relatively easy radiation schedule and low treatment-related toxicities, led to preoperative radiation becoming an integral part of treatment of locally advanced rectal cancer.
Addition of 5-Fluorouracil to Preoperative Radiation
The next step in this process was the addition of concurrent chemotherapy to preoperative radiation. Fluoropyrimidines have been good radiation sensitisers and some notable randomised controlled trials done around the turn of the millennium tested their utility in locally advanced rectal cancer (see Table 1 ). The EORTC study randomised patients to four arms: one employed preoperative radiation alone, and the other three added 5-fluorouracil (5-FU) to radiation in various combinations. At five years, local recurrence rates were halved with the addition of 5-FU. 7 Again, overall survival remained unaffected.
The Fédération Francophone de Cancérologie Digestive (FFCD) trial had only two arms, comparing preoperative chemoradiation to preoperative radiation alone, and demonstrated strikingly similar results. The addition of 5-FU led to the five-year local recurrence being halved, but with similar five-year overall survival. 8 Thus, the clinical utility of adding 5-FU to radiation therapy for rectal cancer was established. Then, the German Rectal Cancer Study Group trial demonstrated that preoperative therapy led to improved five-year local recurrence rate, compared to the same therapy being administered after surgery. The 10-year cumulative incidence of distant metastases (29.8 and 29.6 %; p=0.9). 10 It indicates that more effective systemic treatment is important in the multimodal therapy for locally advanced disease.
Modifications of Preoperative 5-Fluorouracil-based Chemoradiation
Building on the 5-FU-based chemoradiation backbone, the addition of other agents is being evaluated in various trials. Capecitabine, The primary outcome was pathologic complete response (ypCR).
Using historical data, ypCR of 11 % was expected in the control arm 8 and an improvement to 20 % in the experimental arm was the stated goal. However, this outcome was not met. Although an improvement from 14 to 19 % was seen, the difference was not statistically significant. It should be noted that node-positive disease remained in only 30 % of cases, down from 72 % based on preoperative assessment. Nonetheless, based on the statistically non-significant change in the primary outcome of the study, the authors concluded that oxaliplatin should not be used for preoperative chemoradiation for locally advanced rectal cancer. 25 Another large randomised study testing the addition of oxaliplatin to preoperative 5-FU-based chemoradiation was conducted in Italy. Preoperative Treatment of Locally Advanced Rectal Cancer A third study, from Germany, also tested the addition of oxaliplatin to standard 5-FU-based chemoradiation. 27 Approximately 640 patients with locally advanced rectal cancer were randomised to 5-FU, oxaliplatin and radiation, or standard 5-FU and radiation. Preoperative treatment was completed in 74 and 97 % of patients; grade III/IV toxicities occurred in about 22 % of patients in each arm.
Abdominoperineal resection was needed in only 12 % of patients in each arm; postoperative complications were no different. Pathologic complete response, a pre-specified secondary outcome, was seen in 17.6 versus 13.1 % (p=0.033), of patients, meeting pre-specified statistical significance criteria. The study concluded that adding oxaliplatin to 5-FU based XRT was well tolerated and associated with increased pCR rate. However, longer follow-up is necessary to evaluate the primary endpoint of the study, disease-free survival.
Formal publication is awaited.
Should Oxaliplatin be Used for Preoperative Chemoradiation?
This is the obvious question that remains. At first glance, based on the early results discussed above, there is no remarkable improvement in pathologic complete response. However, the long-term outcomes of local recurrence rate and overall survival are awaited. These outcomes are clinically more significant. As mentioned above, the survival advantage conferred by the addition of oxaliplatin to fluoropyrimidine-based adjuvant chemotherapy for resected colorectal cancer has been well-established. 17, 18, 22 In fact, 35 % of patients in the NSABP C-07 trial had cancer of the recto-sigmoid colon. 22 Thus, oxaliplatin may have an important role in securing better long-term outcomes in resected rectal cancer. Based on the available data, it seems the role of oxaliplatin in the neoadjuvant setting is still controversial with moderate increased pCR rate but not impressive as expected and moderately increased toxicity as well.
It may not ready as a general recommendation to add oxaliplatin in preoperative therapy regimens yet, which means fluoroprimidine alone with chemoradiation is still considered current 'standard'
regimen. However, we are waiting for the data regarding disease-free survival and overall survival rates for these Phase III studies. 25, 27 Interestingly, a follow up analysis of the French study (ACCORD 12/0405 PRODIGE 2) showed ¼ of patients on the study were 70 years or older and their tolerability to the chemoradiation was not as good as that of younger patients, which suggested that appropriate therapeutic schedule/regimen needs be considered. 28 Should we reserve it for adjuvant therapy, then? The idea behind preoperative therapy is to improve surgical outcomes, but to also deliver therapy upfront as it is better tolerated (than when given postoperatively) and early institution of systemic therapy may achieve better distant disease control. If the bulk of chemotherapy is reserved for the postoperative setting, there is a significant delay in delivering treatment. After completion of preoperative treatment, a recovery period of 4-6 weeks is followed by surgery, which is again followed by a recovery period of 4-6 weeks before adjuvant therapy can be started. Therefore, 2-3 months elapse without any chemotherapy, and if oxaliplatin is reserved for the adjuvant setting only, then the patient will be administered this agent only after 14-18 weeks since treatment initiation. In addition, due to morbidity from surgery, tolerance of therapy is lower compared to its administration
preoperatively. This has been demonstrated in the German rectal cancer trial 9 and has been consistently seen in therapy for upper gastrointestinal tract tumours, where preoperative therapy is completed by more than 90 % of patients in large studies, whereas less than half are able to complete postoperative therapy. 29 More recently, in a randomised Phase II study comparing preoperative induction chemotherapy and chemoradiation to the standard approach of preoperative chemoradiation followed by surgery and adjuvant chemotherapy, for locally advanced rectal cancer, immediate surgical outcomes were similar, but there was improved chemotherapy completion and lower toxicity when all the therapy was done prior to surgery. 30 Again, only half the patients completed therapy in the postoperative group whereas 92 % completed therapy when all of it was given preoperatively. In another Phase II study evaluating intensification of preoperative therapy, chemotherapy with capecitabine and oxaliplatin was instituted, followed by capecitabine-based chemoradiation and then total mesorectal excision. A 20 % pathologic complete response rate and 83 % three-year overall survival were seen 31 These results indicate that the earlier institution of oxaliplatin may offset the increased toxicity by improving treatment completion rates, thus ultimately achieving better long-term outcomes.
Conclusion
The 
